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SUMMARY
Erythroid commitment and differentiation are regulated by the coordinated action of a host of tran-
scription factors, including GATA2 and GATA1. Here, we explored GATA-mediated transcriptional
regulation through the integrative analysis of gene expression, chromatin modifications, and GATA
factors’ binding in human multipotent hematopoietic stem/progenitor cells, early erythroid progeni-
tors, and late precursors. A progressive loss of H3K27 acetylation and a diminished usage of active
enhancers and super-enhancers were observed during erythroid commitment and differentiation.
GATA factors mediate transcriptional changes through a stage-specific interplay with regulatory ele-
ments: GATA1 binds different sets of regulatory elements in erythroid progenitors and precursors
and controls the transcription of distinct genes during commitment and differentiation. Importantly,
our results highlight a pivotal role of promoters in determining the transcriptional program activated
upon erythroid differentiation. Finally, we demonstrated that GATA1 binding to a stage-specific su-
per-enhancer sustains the expression of the KIT receptor in human erythroid progenitors.
INTRODUCTION
The acquisition of cellular identity during stem cell commitment and differentiation relies on a combination
of genetic and epigenetic information that ultimately determines cellular transcriptional outputs. Master
transcription factors are responsible for the selection of unique enhancer repertoires and activate a
cascade of epigenetic events (e.g., modification of histone tails and loss of DNA methylation) that could
lead to cell-specific modulation of gene expression (Heinz et al., 2015). Recent advances in genome-
wide technologies and bioinformatic data integration allow the elucidation of the molecular mechanisms
underlying cell fate decision and lineage development with unprecedented levels of detail by analyzing
transcriptional and epigenetic changes occurring at different stages of lineage progression.
Human erythropoiesis is an ideal model for studying mechanisms regulating cell commitment and differ-
entiation as the individual developmental cell stages can be isolated and surface markers as well as the
master transcription factors controlling this process are largely known. Erythropoiesis is a multi-step pro-
cess that includes early erythroid commitment of hematopoietic stem cells (HSC), terminal erythroid differ-
entiation, and reticulocyte maturation (Dzierzak and Philipsen, 2013). During early erythroid commitment,
HSC give rise to highly proliferating committed erythroid progenitors, erythroid burst-forming units (BFU-
Es), and then erythroid colony-forming units (CFU-Es). Erythroid progenitors subsequently undergo termi-
nal differentiation, sequentially producing different populations of erythroid precursors (proerythroblasts,
basophilic, polychromatic, and orthochromatic erythroblasts). During this process, cell size is progressively
reduced and the cell membrane is reorganized; the cytoplasm first becomes basophilic, as ribosomes accu-
mulate, and then eosinophilic, due to massive production of hemoglobin, whereas the nucleus becomes
smaller, as a result of the progressive chromatin condensation. Finally, orthochromatic erythroblasts
extrude their nuclei, endoplasmic reticulum, and mitochondria, generating reticulocytes. During matura-
tion, reticulocytes lose the ribosomes and reorganize the cytoskeleton and cell membrane to acquire
the distinctive biconcave shape of red blood cells.
Each developmental stage is characterized by a distinct transcriptional program, with a burst of erythroid-
specific genes’ expression occurring at the early stage of development, followed by the gradual silencing
of the transcriptome in late erythroid precursors (An et al., 2014; Li et al., 2014). These transcriptional
changes are governed by complex regulatory networks, consisting of the functional interplay between
genomic regulatory regions (i.e., promoters and enhancers) and master transcription factors. In particular,
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1
enhancers are the primary determinants of the gene expression program at the early stage of erythropoi-
esis (Huang et al., 2016; Romano et al., 2016; Xu et al., 2012).
GATA2 and GATA1 transcription factors are essential for hematopoietic development and recognize
similar GATA DNA motifs. GATA2 has a fundamental role in the expansion and survival of hematopoietic
stem and progenitor cells (HSPC) and has beenmainly described as a positive regulator of gene expression
(Vicente et al., 2012). GATA1 is the master regulator of erythropoiesis and functions as an activator or
repressor depending on the chromatin context and cofactors (Ferreira et al., 2005). During erythropoiesis,
the GATA2 locus is shut down, whereas GATA1 levels increase, and this transcriptional change (known as
GATA factor switching) is essential for survival and terminal differentiation of erythroid cells (Bresnick et al.,
2010; Moriguchi and Yamamoto, 2014; Suzuki et al., 2013). As an example, in murine erythroid progenitors,
GATA2 enhances the expression of the stem cell factor receptor KIT, which is essential for their prolifera-
tion, whereas GATA1 is responsible for KIT down-regulation, which is required to achieve terminal differ-
entiation (Hong et al., 2005; Jing et al., 2008; Munugalavadla et al., 2005). A GATA2-to-GATA1 exchange
takes place at specific genomic sites containing GATA DNA motifs (‘‘GATA switching sites’’) and is critical
to determine changes in the expression of target genes during erythroid development (Bresnick et al.,
2010; Dore et al., 2012; Huang et al., 2016; Moriguchi and Yamamoto, 2014). Several studies investigated
GATA2 and GATA1 genome-wide occupancy in both mouse (Cheng et al., 2009; Dore et al., 2012; May
et al., 2013; Wu et al., 2011; Yu et al., 2009) and human hematopoietic cells (Beck et al., 2013; Fujiwara
et al., 2009; Hu et al., 2011; Huang et al., 2016; Ludwig et al., 2019; Schulz et al., 2019; Su et al., 2013; Xu
et al., 2012). However, a comprehensive analysis of the dynamics of GATA factor binding to regulatory el-
ements during erythroid commitment and differentiation is still lacking.
Here, we investigated the epigenetic and transcriptional changes occurring during human erythroid devel-
opment. Integrating RNA sequencing (RNA-seq) data, chromation immunopreciptation sequencing (ChIP-
seq) analysis of histone modifications typical of regulatory elements, and GATA factors’ binding profiles in
human HSPC, early erythroid progenitors, and late precursors, we shed light on the regulatory mechanisms
controlling stage-specific transcriptional programs and on the distinct role of GATA1 in the early and late
phases of human erythropoiesis. The novel key points of our study are as follows: (1) a progressive decrease
of H3K27 acetylation, a histone mark typical of active regulatory regions, is a major epigenetic change dur-
ing erythroid development and is associated with a reduction of active enhancers and super-enhancers
(SEs) upon differentiation; (2) promoters are the primary determinants of the gene expression program
at the late stage of erythropoiesis; (3) integration of the chromatin landscape and GATA1 occupancy re-
vealed that GATA1 plays a crucial role in determining the global transcriptional changes occurring during
erythroid development; (4) GATA1 exerts its transcriptional activity by occupying mainly promoters in late
precursors; and (5) differently from mouse cells, GATA1 activates KIT gene expression in human erythroid
progenitors.
RESULTS
Transcriptional Profiling Reveals Major Changes of Gene Expression upon Erythroid
Differentiation
To gain a comprehensive view of gene expression changes occurring during erythroid development, we
performed RNA-seq analysis of human HSPC differentiated in vitro into early committed erythroid progen-
itors (E-Prog; CD34lowCD36+GYPAlow) and late erythroid precursors (E-Prec; CD34CD36+GYPAhigh) (Fig-
ure 1A and S1A–S1C). E-Prog contain BFU-E and CFU-E progenitors (Figure S1C and Romano et al., 2016),
and E-Prec population consists mainly of polychromatic erythroid precursors (Figure S1C and data not
shown). Overall, most genes displayed a lower expression level in E-Prec compared with HSPC and E-
Prog (Figure S1D; An et al., 2014; Wong et al., 2011; Shi et al., 2014). Supervised analysis identified 2,485
differentially expressed genes (DEGs) during commitment (1,203 up-regulated and 1,282 down-regulated
in HSPC-to-E-Prog transition; Figure S1E) and 6,496 DEGs upon differentiation (2,983 up-regulated and
3,513 down-regulated genes in E-Prog-to-E-Prec transition; Figure S1E). We classified all 7,469 unique
DEGs in eight groups, according to their modulation during erythroid development (Figure 1B). Some
DEGs were up- or down-regulated only in one transition (groups 1 and 5 upon commitment and groups
3 and 7 upon differentiation); others were progressively modulated during erythroid development (groups
2 and 6) or showed a non-monotonic expression pattern (groups 4 and 8). Different gene expression pat-
terns reflected specific biological processes (Figure S1F). As reported in other studies (Li et al., 2014; Shi
et al., 2014; Wong et al., 2011), genes progressively up-regulated during erythroid development (group
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2) were related to hemoglobin synthesis and erythrocyte differentiation. Interestingly, we identified novel
classes of genes specifically up-regulated during the differentiation phase (group 3), including genes
involved in DNA packaging and chromosome condensation, in accordance with the heterochromatiniza-
tion known to occur at late stages of erythropoiesis (Ji, 2015). Conversely, HSPC-specific markers (i.e.,
CD34 and CD133) or genes involved in other blood lineages’ biology were down-regulated during commit-
ment (group 5) or progressively down-regulated during erythroid development (group 6), whereas genes
related to ribosome biogenesis were down-regulated in the differentiation phase (group 7), consistently
with the ribosome loss occurring during terminal maturation (Moras et al., 2017). Interestingly, genes up-
regulated upon erythroid commitment and down-regulated during differentiation (group 4) were involved
in metal ion transport, cell morphogenesis, cytokine production, and signaling pathways, and included KIT,
a gene essential for E-Prog survival and proliferation that must be down-regulated to achieve terminal
erythroid maturation (Munugalavadla and Kapur, 2005).
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Figure 1. Changes in the Transcriptomic and Epigenomic Profile during Erythroid Development
(A) Schematic representation of erythroid development. HSPC are committed toward the erythroid lineage giving rise to
E-Prog that then differentiate in E-Prec. Gray bars describe the expression of CD34, CD36, and GYPA surface markers
during erythroid development. See also Figure S1.
(B) Different groups of DEGs, defined according to their modulation (up- or down-regulation) during erythroid
commitment (HSPC to E-Prog) and differentiation (E-Prog to E-Prec). See also Figure S1.
(C–E) Bar plots showing the number of promoters (C), enhancers (D), and super-enhancers (E) identified in each cell
population. Promoters and enhancers were classified as active (H3K27ac+H3K27me3-), weak (H3K27acH3K27me3-), or
bivalent (H3K27acH3K27me3+). Active enhancers were used as constituent enhancers to identify super-enhancers. See
also Figure S2 and Table S1.
(F–H) Heatmaps showing the dynamic usage of promoters (F), enhancers (G), and super-enhancers (H) during erythroid
commitment and differentiation. Each row represents a regulatory region. The color code indicates active, weak, and
bivalent regulatory regions at each stage of erythroid development. White color indicates absence of the regulatory
region. See also Figures S3 and S4 and Tables S2, S3, and S4.
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Active Chromatin Regions Are Lost during Erythroid Commitment and Differentiation
To investigate the chromatin changes occurring during erythroid development, we analyzed the genome-
wide distribution of histone modifications typically associated with promoters (H3K4me3) and enhancers
(H3K4me1), active regulatory regions (H3K27ac), and Polycomb repression (H3K27me3). The fraction of
the genome enriched in H3K4me3 was comparable across all stages, whereas genome coverage for all
other histone modifications was reduced in E-Prog and E-Prec compared with HSPC. In particular, the
coverage of H3K27ac and the amount of H3 histones harboring this modification progressively decreased
during erythroid development (Figures S2A and S2B).
To define the epigenetic landscape in a systematic manner, we exploited a machine learning approach to iden-
tify chromatin states using these four histone marks with a resolution of 200 bp.We defined five promoter states
(H3K4me3+), four enhancer states (H3K4me1+), a polycomb-repressed state (H3K27me3+), and a quiescent state
devoid of any histone mark (Figures S2C and S2D). Based on the presence of H3K27ac or H3K27me3, we clas-
sified promoter and enhancer states as active (H3K27ac+H3K27me3-), weak (H3K27acH3K27me3-), or bivalent
(H3K27acH3K27me3+; Ernst et al., 2011; Roadmap Epigenomics Consortium et al., 2015). Finally, we merged
contiguous genomic segments (see Methods) to define different sets (active, weak, and bivalent) of promoter
and enhancer regions (with a minimum size of 400 bp) for each stage of erythroid development (Tables S1,
S2, and S3).Moreover, we defined SEs as clusters of active enhancers (Tables S1 and S4;Whyte et al., 2013; Hnisz
et al., 2013). To validate our approach, we analyzed the expression levels of genes associated with different clas-
ses of regulatory elements. Genes associated with active regulatory regions showed higher expression levels
comparedwithgenes associatedwithweak or bivalent regions, whichwere expressed atmediumand low levels,
respectively (Figures S2E and S2F). We identified around 20,000 promoters in HSPC and E-Prog and 15,868 in E-
Prec (Figure 1C), more than 45,000 enhancers in HSPC and E-Prog and only 21,337 in E-Prec Figure 1D, and 497
SEs in HSPC, 436 in E-Prog, and only 135 in E-Prec (Figure 1E). Most of the regulatory elements were active in
HSPC, whereas the fraction of active promoters (Figures 1C and S2D), enhancers (Figures 1D and S2D), and
SEs (Figure 1E) diminished in E-Prog and E-Prec in accordance with the progressive loss of H3K27ac during
erythroid development.
Interestingly, most promoters were shared during erythroid development, with only 10% being stage spe-
cific (Figures 1F and S3A). Promoters that maintained an active state throughout erythroid development
drove the expression of genes involved in common cell functions, as cell metabolism, cell cycle, and chro-
matin organization (Figure S3B). Bivalent promoters that maintained their state in both commitment and
differentiation or completely lost H3K4me3 were associated with genes involved in non-hematopoietic tis-
sue and organ development that need to be repressed to maintain lineage fidelity (Figure S3B). Interest-
ingly, genes related to erythropoiesis were associated with either active promoters that maintained their
state during the entire erythroid development or E-Prec-specific promoters.
Enhancer usage dramatically changed during commitment and differentiation, resulting in almost 40% en-
hancers being stage-specific in each cell type (Figures 1G and S3C). Genes targeted by active and weak
stage-specific enhancers in HSPC were mainly involved in leukocyte differentiation, whereas in E-Prog
they were related to chromosome organization, cytoskeleton and plasma membrane organization, and
cell cycle, and in E-Prec they were related to erythrocyte differentiation, chromatin organization, and auto-
phagy (Figure S3D).
SEs’ usage was almost completely stage specific, with less than 30% SEs identified in a single cell type
shared with the other stages (Figures 1H and S4A). HSPC-specific SEs were annotated to genes involved
in leukocyte biology (Figure S4B) and to stem cell markers as DNMT3A, CD34, PROM1 (CD133), RUNX2/
RUNX3, FLI1, ERG, and GFI1 (Figure S4C). Instead, genes targeted by E-Prog- and E-Prec-specific SEs
were mostly related to erythrocyte biology, such as CD55, RHAG, HBS1L, CD36, SLC44A1, SLC40A1,
and SPTA1 in E-Prog and RHD RBM38, HEMGN, TMEM56, SLC2A1, SLC22A23, SLC25A37, SLC22A4,
and HBE1 (beta-globin locus control region) in E-Prec (Figures S4D and S4E). Only few loci (n = 60; e.g.,
KIT gene) displayed a combination of common and stage-specific SEs, suggesting a fine modulation of
the expression of these genes during erythroid differentiation (see Figure 4).
GATA Transcription Factors’ Occupancy during Erythroid Commitment and Differentiation
To elucidate how GATA factors regulate gene expression during erythroid development, we analyzed
GATA2 and GATA1 binding profiles in HSPC, E-Prog, and E-Prec. Although GATA2 mRNA levels were
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comparable in HSPC and E-Prog (Figure 2A), GATA2 protein was present at high levels in HSPC and
decreased during erythroid development (Figure 2B). GATA1 protein was mainly present in E-Prog and
substantially reduced in E-Prec (Figures 2B and S5A and Ludwig et al., 2019) despite the progressive
increase of GATA1 mRNA expression during differentiation (Figure 2A). The dynamic expression of
GATA proteins clearly emerged when analyzing GATA factors’ genome-wide occupancy. Indeed, the
large number of GATA2-binding sites (BS) identified in HSPC (n = 15,171) drastically decreased in
E-Prog cells (n = 419) and was reduced to zero in E-Prec (Figure 2C, Table S5 and Figures S5B
and S5C). Similarly, we identified more than 23,000 GATA1 BS in E-Prog and almost half of these
in E-Prec (n = 11,005), whereas no GATA1 BS was recovered in HSPC (Figure 2C, Table S5 and Figures
S5B and S5C). Virtually all GATA2 BS were HSPC specific, and one-third of them underwent a GATA2-
to-GATA1 switch during HSPC-to-E-Prog transition and 40% of these remained bound by GATA1 in E-
Prec (Figure 2C). E-Prog and E-Prec shared 7,000 GATA1 BS, whereas 16,000 and 4,000 stage-
specific GATA1 BS were identified in E-Prog and E-Prec, respectively (Figure 2C). These data indicate
that GATA1 occupies and regulates common and different genes during the early and late stages of
erythroid development.
Genomic regions targeted by GATA2 were enriched in DNAmotifs for ETS and RUNX factors, preferentially
expressed in earlier stages of erythroid development, whereas GATA1-targeted regions contained motifs
for the erythroid-specific KLF1 factor, and, in E-Prec, for the ubiquitous SP1 and NFY factors that occupy
preferentially promoter elements (Figure S5D).
Mapping GATA BS to regulatory regions revealed that the two factors targeted only a small fraction of pro-
moters and enhancers, whereas GATA2 and GATA1 occupied the majority of SEs in HSPC and in E-Prog/E-
Prec, respectively (Figures S6A–S6C and Tables S2, S3, and S4). Among BS mapped to regulatory regions,
72% HSPC GATA2 BS were located within enhancers and SEs. GATA1 occupies both enhancers/SEs (58%)
and promoters (42%) in E-Prog, whereas in E-Prec, GATA1 mainly targeted promoter regions (72%, Fig-
ure 2D). These results indicate that GATA1 may exert its transcriptional activity by occupying both en-
hancers and promoters in committed erythroid progenitors and mainly promoters in more differentiated
precursors.
We then associated GATA-occupied regulatory regions with their target genes. Around half of GATA2-
targeted genes in HSPC were targeted by GATA1 in E-Prog (Figure 2E) and more than 75% of them
presented at least one GATA switching site. Interestingly, GATA1 occupied common and different sets
of genes in E-Prog and E-Prec (Figure 2E). Genes targeted only by GATA2 in HSPC (group A) were
down-regulated during erythroid development (Figure 2F) and are involved in immune system biolog-
ical processes (Figure 2G). This analysis suggests that these genes are activated by GATA2 in HSPC,
whereas loss of GATA2 binding during erythroid development leads to their down-regulation. Genes
undergoing GATA2-to-GATA1 exchange upon erythroid commitment were either up-regulated or their
expression remained stable, suggesting that GATA1 increases or sustains their expression in E-Prog,
whereas GATA2 might repress them or maintain their low expression in HSPC. Then, these genes
were either turned off during differentiation, when losing GATA1 binding in E-Prec (group B; Figures
S6D and S6E), or up-regulated during erythroid development, if still targeted by GATA1 in E-Prec
(group C; Figures 2F, S6D, and S6E). Group B was functionally enriched in immune cell activation
and hematopoiesis, whereas group C was enriched in erythropoiesis, histone modifications, cell cycle,
and autophagy (Figure 2G). In E-Prog and E-Prec (group F), GATA1 occupied genes that were up-
regulated during erythroid development (Figures 2F, S6D, and S6E) and related to heme metabolic
process, membrane lipid distribution, and chromatin organization (Figure 2G). Finally, genes specif-
ically targeted by GATA1 in E-Prec (group G) were up-regulated upon differentiation and involved
in cell cycle and autophagy (Figures 2F and 2G). These results suggest that GATA1 exerts mainly acti-
vating functions during human erythroid development.
Transcriptional Changes in Erythropoiesis Are Associated with a Complex Interplay between
Regulatory Elements and GATA Factors’ Binding
To unveil how the interplay between regulatory elements and GATA factors influences transcriptional
regulation during erythropoiesis, we assigned the different regulatory elements to each DEG and eval-
uated the enrichment in GATA factor BS at each stage of erythroid development (Figure 3). In partic-
ular, we generated a gene-centered matrix that contains the total coverage of all promoters and
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enhancers assigned to each DEG at each cell stage. This procedure allowed grouping of DEGs in 19
clusters based on their different chromatin landscapes. These clusters were either controlled by pro-
moters only (clusters 1, 2, 8, 13, and 17) or by the combined action of promoters and enhancers (Fig-
ure 3A). Interestingly, the chromatin landscape of DEGs was more heterogeneous than their transcrip-
tional status, as genes associated with different chromatin landscapes showed the same expression
pattern during erythroid development (Figures 3A and 3B). In particular, clusters from 1 to 7
comprised genes that were mostly up-regulated during erythroid commitment and differentiation
(e.g., genes involved in erythrocyte biology and chromatin reorganization; Figures 3B and 3C) despite
their different chromatin landscapes (Figure 3A). Promoters of these genes were already marked by
H3K27ac in HSPC, before erythroid induction, and maintained an active state during the entire devel-
opment (Figure 3A). These data indicate that promoters of up-regulated genes are bookmarked in
earlier stages of erythroid development. Active enhancers, if present, either did not change their state
during erythroid development or were even lost, particularly upon terminal differentiation (Figure 3A),
indicating that enhancers play a minor role in the transcriptional up-regulation occurring during E-
Prog-to-E-Prec transition. On the contrary, genes in clusters from 8 to 16 (e.g., genes related to leuko-
cyte biology and non-hematopoietic development) showed a sharp change in their chromatin land-
scape, characterized by the loss of active regulatory elements during erythroid development accom-
panied by the concomitant decrease in the expression levels (Figures 3A–3C).
To investigate this partial dichotomy between epigenetic and transcriptional profiles, we evaluated the
enrichment in GATA factors’ BS within promoters and enhancers associated with each cluster of DEGs.
As expected, GATA2 targeted mostly enhancers in HSPC, whereas GATA1 binds both promoters and
enhancers in E-Prog and mainly promoters in E-Prec (Figures 3D and 3E). Considering clusters of up-
regulated genes (from 1 to 7), GATA2 BS were enriched at promoters or enhancers of few clusters in
HSPC, whereas in E-Prog and E-Prec, GATA1 binding was enriched within active promoters of virtually
all clusters and within active and weak enhancers of some of them (Figures 3D and 3E). These findings
indicate that GATA1 plays a role in up-regulating these genes during erythroid development mainly
through the binding of active promoters, especially in late precursors, whereas GATA2 likely maintains
their low activity in HSPC. Clusters of down-regulated genes (from 8 to 16) were characterized by an
enrichment of GATA2 BS at active and weak enhancers in HSPC and by an enrichment of GATA1 BS
at weak promoters and active and weak enhancers in E-Prog and at weak and bivalent promoters and
weak enhancers in E-Prec (Figures 3D and 3E). This suggests that, in HSPC, GATA2 binding at enhancers
might play a role in boosting the expression of these genes, which is still sustained by GATA1 in E-Prog.
Then, the loss of GATA1 binding at active enhancers or the binding of GATA1 to weak or bivalent pro-
moters might induce the transcriptional silencing of these genes in E-Prec. In E-Prog, GATA1 BS were
also enriched at bivalent promoters of lowly expressed genes involved in the development of unrelated
tissues (clusters 17–19; Figure 3C) indicating that, when binding at bivalent promoters, GATA1 might act
as a transcriptional repressor.
Overall, virtually all the clusters enriched in GATA2 BS within enhancers in HSPC showed enrichment in
GATA1 BS in E-Prog and E-Prec, suggesting that the transition from GATA2- to GATA1-mediated gene
regulation occurs mainly at enhancer regions (Figure 3E). Of note, 37% enhancers targeted by GATA2 in
HSPC contain GATA switching sites.
Figure 2. GATA Factors Occupancy during Erythroid Development
(A) Expression levels of GATA2 and GATA1 in HSPC, E-Prog, and E-Prec by RNA-seq. Data were plotted as mean with SEM.
(B) Western blot analysis of GATA2 and GATA1 in the nuclear fraction of HSPC, E-Prog, and E-Prec. Total H3 was used for normalization. See also Figure S5.
(C) Heatmap showing GATA2 and GATA1 BS dynamics during erythroid commitment and differentiation. Each row represents a GATA factor BS. The
number of BS identified in each population is reported below the heatmap. Dashed lines separate common and stage-specific BS. See also Figure S5 and
Table S5.
(D) GATA2 and GATA1 BS distribution within regulatory regions in HSPC, E-Prog, and E-Prec. See also Figure S6.
(E) Heatmap showing different groups of GATA2-and GATA1-targeted genes in HSPC, E-Prog, and E-Prec. We defined GATA2- and GATA1-targeted genes
as the three nearest genes (with a maximum distance of 100 kb) to each GATA-targeted regulatory region. Each target gene can be associated with one or
more GATA BS.
(F) Heatmap showing the enrichment of the different groups of GATA factor target genes, as defined in (E), in genes with different expression patterns (as
defined in Figure 1B). Gray-scale indicates enrichment p value. See also Figure S6.
(G) Gene ontology enrichment analysis of GATA2- and GATA1-targeted genes. Enriched Biological Process (BP) terms are shown on the y axis; different
groups of GATA factor target genes, as defined in (E), are shown on the x axis. Dots are color coded based on the enrichment q-values; dot size indicates the
fraction of genes in each BP term.
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GATA1-bound regions associated with induced genes were enriched in motifs for KLF1 and E2F4 factors (Fig-
ure S7), which are up-regulated during erythroid development and play a fundamental role in erythroid differ-
entiation and proliferation (Kinross et al., 2006; Siatecka and Bieker, 2011). Conversely, GATA1-occupied regions
associated with down-regulated genes contained motifs for ETS factors (e.g., ERG, FLI1, and PU.1; Figure S7),
mostly expressed in HSPC and down-regulated during erythroid development, and fundamental for the main-
tenance of HSC and the development of other hematopoietic lineages (Athanasiou et al., 2000; Calero-Nieto
et al., 2010; Knudsen et al., 2015; Nishiyama et al., 1999; Rekhtman et al., 1999; Wontakal et al., 2012). Thus
the low expression of ETS factors in erythroid cells and the consequent lack of ETS factor binding to these genes
could contribute to the silencing of genes involved in non-erythroid functions (Wontakal et al., 2012). Finally,
composite GATA:TAL1 motifs were enriched in GATA-occupied regulatory regions associated with both up-
and down-regulated genes (Figure S7), suggesting a role for TAL1 in both gene activation and gene repression
(Huang and Brandt, 2000; Pinello et al., 2014; Schuh et al., 2005; Van Handel et al., 2012).
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Figure 3. Chromatin Landscape Defines Clusters of DEGs
(A) Heatmap representing the clustering of the gene-centeredmatrix containing the total coverage of the promoters and enhancers annotated to each DEG.
DEGs are clustered according to the total extension of the associated regulatory regions. Each column represents a DEG, and each row, the extension (in kb)
of the associated regulatory elements in each cell stage. Color scale indicates the total extension as log10(coverage [kb]).
(B) Heatmap showing cluster enrichment in genes with different expression patterns (as defined in Figure 1B). Color scale indicates the statistical significance
of the enrichment calculated by a Fisher’s exact test.
(C) Biological process terms (BPs) enriched in each group are shown on the y axis; DEG clusters, as defined in Figure 3A, are shown on the x axis. Dots are
color coded based on the enrichment q-values; dot size indicates the fraction of genes in each Gene Ontology term. DEGs of clusters 1–7, mostly up-
regulated during erythroid commitment and differentiation, are functionally annotated to erythropoiesis, chromatin organization, cell cycle, and autophagy
BPs. Genes within clusters from 8 to 19, mostly down-regulated during erythroid development, were related to immune cell biology (12, 14–16) or to the
development of unrelated tissues (17–19).
(D and E) Heatmaps showing cluster enrichment in GATA factors BS within promoters (D) and in GATA factor BS within enhancers (E). Color scale indicates
the statistical significance of the enrichment calculated by a Fisher’s exact test.
See also Figure S7.
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ANovel GATA1-Dependent Super-enhancer Sustains KIT Expression in Erythroid Progenitors
To prove that this interplay between regulatory elements and GATA factors’ binding is crucial to control
gene expression during erythroid development, we focused on the KIT gene. A precise regulation of
KIT expression is required for erythroid progenitor survival and proliferation and to achieve terminal
erythroid maturation (Munugalavadla and Kapur, 2005). Indeed, we found that, in HSPC, KIT mRNA levels
were relatively low and 65% cells poorly expressed KIT on the cell surface (median fluorescence intensity
[MFI] = 17) (Figures 4A and 4B). Upon commitment, KIT transcription significantly increased (14 fold) and
almost all E-Prog (93%) expressed KIT at high levels (MFI = 189) (Figures 4A and 4B). In E-Prec, KIT gene
was substantially down-regulated with less than 55% cells still expressing low levels of KIT (MFI = 65) (Fig-
ures 4A and 4B).
In mouse KIT+ progenitor cells, GATA2 activates KIT expression through the binding of an enhancer
located 114 kb upstream of the gene (Jing et al., 2008). Upon erythroid differentiation, this enhancer is
occupied by GATA1, which induces KIT down-regulation (Jing et al., 2008). The analysis of regulatory ele-
ments during human erythroid development revealed that both KIT promoter and KIT-associated en-
hancers were active in HSPC and E-Prog and lost H3K27ac upon differentiation (Figure 4C; cluster 9 in Fig-
ure 3A). Moreover, KIT regulatory elements were targeted by GATA2 in HSPC and by GATA1 upon
erythroid commitment (Figure 4C; group B in Figure 2F and cluster 9 of Figure 3D). In particular, we iden-
tified three SEs that could contribute to KIT transcriptional regulation during erythropoiesis, i.e., an SE
located within KIT first intron in both HSPC and E-Prog, an HSPC-specific SE located +160/+180 kb down-
stream of KIT TSS (Aranda-Orgilles et al., 2016), and an E-Prog-specific SE located118/-70 kb upstream of
KIT TSS (Figure 4C). This latter SE comprised two main constituent active enhancers (Enhancer I and II)
marked by high H3K27ac levels and bound by GATA1. Interestingly, upon differentiation, both Enhancer
I and II lost H3K27ac and Enhancer II lost GATA1 binding (Figure 4C). In addition, the E-Prog-specific SE
contains two additional GATA1-occupied active enhancers that show lower H3K27ac levels compared
with Enhancers I and II: (1) Enhancer III that is homologous to the murine 114-kb enhancer but is not tar-
geted by GATA2 in KIT+ progenitors as in the mouse system and (2) Enhancer IV that is occupied by GATA2
in HSPC (as a weak enhancer) and is targeted by GATA1 upon erythroid commitment (Figure 4C). Of note,
in HSPC, besides Enhancer IV, GATA2 occupies also a weak enhancer upstream of the E-Prog-specific SE,
suggesting that it may contribute to sustain KIT expression in HSPC (Figure 4). Interestingly, two SNPs
(rs2703485 and rs218264) associated with red blood cell phenotypes map to the GATA1 BS in Enhancer I
and Enhancer IV, respectively (Figure 4C; Astle et al., 2016).
To demonstrate that GATA1 binding to the highly acetylated Enhancer I and II is essential to sustain KIT
expression in human erythroid progenitors, we performed chromatin conformation capture (3C) and
Cas9-mediated genome editing in HUDEP-2 cells. HUDEP-2 is an immortalized erythroid progenitor cell
line (Kurita et al., 2013) that, similarly to E-Prog, expresses high levels of KIT when undifferentiated
(Day0) and that, as in the E-Prog-to-E-Prec transition, down-regulates KIT upon differentiation (Day 7) (Fig-
ures S8A and S8B). Moreover, undifferentiated HUDEP-2 cells present accessible chromatin regions map-
ping to the E-Prog-specific KIT enhancers (Figure S8C), suggesting that these regulatory elements are
active in this cell line (Masuda et al., 2016). 3C experiments evidenced that, only in undifferentiated KIThigh
HUDEP-2 cells, the KIT promoter interacts with Enhancer I and II (Figure 4D) and that Enhancer I and II
interact with each other (Figures S8D and S8E). This indicates the presence, in human erythroid progeni-
tors, of an active chromatin hub containing the KIT promoter and its active regulatory elements. We
then transfected KIThigh HUDEP-2 cells with plasmids expressing a Cas9-GFP fusion protein and guide
RNAs deleting Enhancer I or II or specifically disrupting their respective GATA1 BS (Figure 5A). Both the
deletion of KIT Enhancer I or II and the disruption of GATA1 BS strongly reduced KIT gene expression,
the percentage of KIT-expressing cells, and KIT MFI in the GFP+-edited fraction (Figures 5B–5E and S9),
indicating that GATA1 binding at Enhancer I and II plays a crucial role in boosting KIT expression in
erythroid progenitor cells. Notably, the lower expression of KIT was accompanied by a marked increase
in the expression of the erythroid differentiation marker GYPA, with a trend in decreased GATA2 and
increased GATA1 mRNA levels (Figure 5F).
DISCUSSION
In this study, we analyzed the usage of regulatory elements and GATA factor dynamic occupancy in multi-
potent human primary HSPCs and in their erythroid progeny, including human early erythroid progenitors
(Romano et al., 2016) and late polychromatic erythroid precursors.
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Figure 4. Epigenetic Regulation and Chromatin Interactions in the Human KIT Locus during Erythroid Development
(A) KIT mRNA expression levels in HSPC, E-Prog, and E-Prec, as determined by RT-qPCR. Data were plotted as mean with SEM. *p < 0.05 (unpaired t test).
(B) Flow cytometry analysis of KIT expression during erythroid commitment and differentiation. The percentage of KIT+ cells and the MFI (median
fluorescence intensity) are shown. Data were plotted as mean with SEM. **p < 0.01; ***p < 0.001; ****p < 0.0001 (unpaired t test).
(C) Regulatory elements and GATA factors BS within the KIT locus. Green boxes indicate SEs. Orange dashed boxes indicate the constituent enhancers
within the E-Prog-specific super-enhancer. Enhancer I and II (E-I and E-II) show the highest H3K27ac peaks. Enhancer III (E-III) is homologous to the mouse
114 enhancer. Enhancer IV (E-IV) undergoes GATA2-to-GATA1 switch. SNPs mapping to the E-Prog-specific super-enhancer are indicated.
(D) Chromatin interactions within the KIT locus in undifferentiated (Day 0) and differentiated (Day 7) HUDEP-2 cells. We used as anchor a genomic fragment
containing the KIT promoter (flanked by solid black lines). HindIII digestion fragments of interest are flanked by dashed black lines. Distances on the x axis are
in kb counting from the transcription start site (TSS) of the KIT gene. KIT promoter interacts with Enhancer I and II only in KIThigh HUDEP-2 undifferentiated
cells. See also Figure S8.
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Figure 5. CRISPR/Cas9-Mediated Disruption of E-Prog-Specific KIT Regulatory Elements
(A) Schematic representation of the genomic regions and GATA1 BS in the KIT locus targeted using the CRISPR/Cas9
system. Red boxes indicate unedited wild-type Enhancer I or II, and white dots indicate unedited wild-type GATA1 BS
within the enhancers (Ctr). Black boxes indicate Enhancer I or II deletion (D Enh. I and D Enh. II). Black dots indicate GATA1
BS disruption (D BS I and D BS II).
(B) KIT expression levels in control and edited cells, as determined by RT-qPCR. Control samples (Ctr) were transfected
with plasmids encoding for Cas9-GFP and a guide RNA targeting the luciferase gene. mRNA levels were expressed as
fold change versus control cells. Data were plotted as mean with SEM.
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During erythropoiesis, inhibition of histone acetylation and increase in histone deacetylation play a critical role in
chromatin condensation and enucleation of erythroid precursors (Ji et al., 2010, 2011; Popova et al., 2009). Our
analysis of the epigenetic landscapes of human HSPC, early erythroid progenitors, and late precursors revealed
for the first time a progressive decrease of H3K27ac abundance and genome-wide coverage during erythroid
development, accompanied by the up-regulation of genes involved in chromatin condensation and by the over-
all reduction in gene expression upondifferentiation. These results suggest that the decrease of H3K27ac during
erythropoiesis contributes to the heterochromatin formation and the consequent global gene silencing at late
stage of erythroid development. This extensive epigenetic change influences the regulatory mechanisms con-
trolling transcription, in particular in late erythroid precursors. Indeed, we found a reduced number of active
H3K27ac+ regulatory elements, in particular enhancers and SEs, upon differentiation, suggesting that enhancer
decommissioning occurs at the late stage of erythropoiesis. In accordance, gene expression in late precursors is
mainly sustained by promoters and weak H3K27ac enhancers, and the few SEs identified in E-Prec control the
transcription of only a subset of stage-specific highly expressed genes. Our findings are consistent with the
decreased number of chromatin accessibility peaks in polychromatic human erythroid precursors (Ludwig
et al., 2019; Schulz et al., 2019).
The coordinate action of GATA factors has a fundamental role in the transcriptional regulation of erythro-
poiesis. The ‘‘GATA factor switching’’ (Bresnick et al., 2010; Moriguchi and Yamamoto, 2014; Suzuki et al.,
2013) occurred in E-Prog, where GATA2 protein levels decreased, whereas the amount of GATA1 protein
increased, resulting in a prevalent and specific chromatin occupancy of GATA2 in HSPC and GATA1 in E-
Prog. Several genes regulated by GATA2 in HSPC were targeted by GATA1 in E-Prog, and the transition
from GATA2 to GATA1-mediated gene regulation can occur via a GATA2-to-GATA1 exchange at the
same BS (GATA switching sites) and/or through the alternative binding of GATA2 and GATA1 to different
sites within the regulatory regions associated with the target gene. Interestingly, for differentially ex-
pressed genes, GATA switch occurs mostly at enhancer regions, and either leads to gene up-regulation
or does not significantly change gene expression in E-Prog.
However, most GATA1 functions during erythropoiesis occur via de novo binding at open chromatin re-
gions. Interestingly, GATA1 targeted common and distinct sets of genes in E-Prog and E-Prec, displaying
different binding preferences. Indeed, in E-Prog, GATA1 occupied both promoters and enhancers (or SEs),
whereas in E-Prec GATA1 mainly bound promoters. This change in GATA1 binding preferences during E-
Prog-to-E-Prec transition together with the diminished enhancer usage observed in E-Prec highlights a
novel pivotal role of promoter regions as determinants of the transcriptional program activated during ter-
minal erythroid differentiation. This novel finding is a unique feature of erythroid precursors, as previous
studies indicate that enhancers play a main role in defining cell fate at the early stage of development
(Huang et al., 2016; Romano et al., 2016; Xu et al., 2012).
To better investigate the interplay between regulatory elements and GATA factors in determining gene
transcription during erythropoiesis, we used an integrative bioinformatics approach. Our results showed
that investigating the chromatin landscape dynamic alone is not sufficient to infer the transcriptional mod-
ulations that occur during erythroid development, and that integrating the binding profiles of key master
regulators, as GATA2 and GATA1, is essential to understand the epigenetic mechanisms governing the
transcriptional changes. Moreover, our findings evidenced that GATA1 binding in different chromatin con-
texts consistently correlates with its dual activity as transcriptional activator or repressor. In fact, GATA1
binding at active regulatory regions (mainly promoters) is associated with a positive transcriptional regu-
lation of the target gene (as for genes related to erythrocyte differentiation and homeostasis). Conversely,
GATA1 binding at weak (in E-Prec) or bivalent (in both E-Prog and E-Prec) promoters correlates with the
transcriptional silencing of the target genes (as for genes related to leukocyte differentiation or develop-
ment of unrelated tissues).
Figure 5. Continued
(C–E) Flow cytometry analysis of GFP and KIT expression in control and edited cells. For all the edited samples, both
percentage of KIThigh cells (C and D) and KIT MFI (C and E) in the GFP+ populations were reduced compared with control
cells. Percentage of KIThigh cells and KIT MFI were expressed as fold change versus control cells. Data were plotted as
mean with SEM.
(F) GYPA, GATA2, and GATA1 expression levels by RT-qPCR in control and edited cells. mRNA levels were expressed as
fold change versus control cells. Data were plotted as mean with SEM.
(B and D–F) *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001 (unpaired t test).
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Importantly, we performed validation studies of regulatory elements identified in the KIT locus. In mouse
erythroid cells, several regulatory elements were identified upstream of the KIT gene or within its introns,
and GATA2 is known to activate KIT expression in early progenitors, whereas GATA1 is responsible for KIT
down-regulation upon differentiation (Cairns, 2003; Hong et al., 2005; Jing et al., 2008; Munugalavadla
et al., 2005). However, little is known about the transcriptional regulation of KIT gene in human cells (Ara-
nda-Orgilles et al., 2016; Romano et al., 2016). Here, we identified an E-Prog-specific SE upstream of KIT
gene targeted by GATA1. Our results demonstrate that GATA1 binding at the E-Prog-specific SE is
required for high-level KIT expression in human erythroid progenitors. Interestingly, the enhancer homol-
ogous to the murine114-kb regulatory region (which was associated with high KIT expression when occu-
pied by GATA2 in mouse progenitors and to KIT down-regulation when occupied by GATA1 in mouse
erythroid precursors; Jing et al., 2008) is not targeted by GATA2 but only by GATA1 in KIT+ E-Prog. Alto-
gether, these data indicate that, differently from mouse erythroid cells, GATA1 activates KIT expression in
human erythroid progenitors, supporting its up-regulation during erythroid commitment.
Several genes are known to be differentially regulated in human versus murine erythropoiesis (An et al.,
2014). Notably, some genes upregulated during human erythropoiesis and down-regulated during murine
erythropoiesis (e.g., RAPGEF2, MAP2K3, and RNF187; An et al., 2014) were indeed associated with active
regulatory regions targeted by GATA1 in E-Prog and E-Prec (Figures S6D and S6E).
Overall, our stage-specific analysis of the transcriptional and epigenetic profiles and GATA factors’ occu-
pancy at key stages of human erythropoiesis provides new insights into the complex transcriptional regu-
latory mechanisms that control human erythroid commitment and differentiation, dissecting the pivotal
role of GATA1 at both early and late stages of erythropoiesis.
Limitations of the Study
Given the high number of cells required to detect GATA factor binding by ChIP-seq, we analyzed mixed
populations of erythroid progenitors (E-Prog: BFU-E, and CFU-E) and precursors (E-Prec: mainly polychro-
matic precursors). Therefore, our analyses may have a lower definition compared with transcriptomic and
epigenomic studies analyzing highly purified erythroid progenitors and precursors (An et al., 2014; Li et al.,
2014; Ludwig et al., 2019; Schulz et al., 2019).
METHODS
All methods can be found in the accompanying Transparent Methods supplemental file.
DATA AND CODE AVAILABILITY
The accession number for all RNA-seq and ChIP-seq data reported in this paper is GEO:GSE124165.
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Figure S7
Motif Name Consensus UP-regulated gene
DOWN-regulated 
genes
UP-regulated 
gene
DOWN-regulated 
genes
GATA(Zf) SAGATAAGRV 3.17 3.27 3.20 3.21
GATA(Zf):TAL1(E-box) CRGCTGBNGNSNNSAGATAA 3.78 3.98 4.37 3.98
ERG(ETS) ACAGGAAGTG 0.45 0.88 0.10 0.66
Fli1(ETS) NRYTTCCGGH 0.64 1.11 0.35 0.82
GABPA(ETS) RACCGGAAGT 0.53 0.84 0.31 0.86
PU.1(ETS) AGAGGAAGTG 0.82 1.45 0.02 0.83
ELF1(ETS) AVCCGGAAGT 0.32 0.85 0.53 0.98
ETS(ETS) - Promoter AACCGGAAGT 0.46 1.12 0.42 1.45
KLF1(Zf) NWGGGTGTGGCY 1.65 0.69 1.54 1.20
E2F4(E2F) GGCGGGAAAH 0.72 0.15 0.68 0.40
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Figure S9
A
B
Sequence InDel Type InDel Lenght (nt)
InDel 
Frequency
GATA motif 
disruption
CCTCCGCAGGCCTCTGCTCCCAGCA|GATAATAGACTGGTCATGAGGTATTTTTAAGCAGTTGCTTAAAAAGACAG WT 0 52.2% no
CCTCCGCAGGCCTCTGCTCCCAGCA|--TAATAGACTGGTCATGAGGTATTTTTAAGCAGTTGCTTAAAAAGACAG DEL -2 8.3% yes
CCTCCGCAGGCCTCTGCTCCCAGCA|-------GACTGGTCATGAGGTATTTTTAAGCAGTTGCTTAAAAAGACAG DEL -7 5.7% yes
CCTCCGCAGGCCTCTGCTCCCAGCA|-ATAATAGACTGGTCATGAGGTATTTTTAAGCAGTTGCTTAAAAAGACAG DEL -1 4.3% yes
CCTCCGCAGGCCTCTGCTCCCAGC-|GATAATAGACTGGTCATGAGGTATTTTTAAGCAGTTGCTTAAAAAGACAG DEL -1 3.5% yes
CCTCCGCAGGCCTCTGCTCCCAGCA|---AATAGACTGGTCATGAGGTATTTTTAAGCAGTTGCTTAAAAAGACAG DEL -3 3.2% yes
CCTCCGCAGGCCTCTGCTCCCAG--|GATAATAGACTGGTCATGAGGTATTTTTAAGCAGTTGCTTAAAAAGACAG DEL -2 2.9% yes
CCTCCGCAGGCCTCTGCTCCCAGCA|nGATAATAGACTGGTCATGAGGTATTTTTAAGCAGTTGCTTAAAAAGACA INS 1 2.8% yes
CCTCCGCAGGCCTCTGCTCCC----|-ATAATAGACTGGTCATGAGGTATTTTTAAGCAGTTGCTTAAAAAGACAG DEL -5 2.4% yes
CCTCCGCAGGCCTCTGCTCCCAGCA|nnnnGATAATAGACTGGTCATGAGGTATTTTTAAGCAGTTGCTTAAAAAG INS 4 1.6% possible
CCTCCGCAGGCCTCTGCTCCCAGCA|nnGATAATAGACTGGTCATGAGGTATTTTTAAGCAGTTGCTTAAAAAGAC INS 2 1.5% possible
CCTCCGCAGGCCTCTGCTCCCAGCA|------AGACTGGTCATGAGGTATTTTTAAGCAGTTGCTTAAAAAGACAG DEL -6 1.3% yes
CCTCCGCAGGCCTCTGCTCCCAGCA|----ATAGACTGGTCATGAGGTATTTTTAAGCAGTTGCTTAAAAAGACAG DEL -4 1.0% yes
CCTCCGCAGGCCTCTGCTCCCA---|GATAATAGACTGGTCATGAGGTATTTTTAAGCAGTTGCTTAAAAAGACAG DEL -3 1.0% yes
CCTCCGCAGGCCTCTGCTCCCAGCA|nnnGATAATAGACTGGTCATGAGGTATTTTTAAGCAGTTGCTTAAAAAGA INS 3 0.9% possible
CCTCCGCAGGCCTCTGCTCCCAGCA|nnnnnnnnnnnnnnnGATAATAGACTGGTCATGAGGTATTTTTAAGCAGT INS 15 0.8% possible
CCTCCGCAGGCCTCTGCTCCC----|------AGACTGGTCATGAGGTATTTTTAAGCAGTTGCTTAAAAAGACAG DEL -10 0.8% yes
CCTCCGCAGGCCTCTGCTCCC----|------------GTCATGAGGTATTTTTAAGCAGTTGCTTAAAAAGACAG DEL -16 0.5% yes
CCTCCGCAGGCCTCTGCTCCCAGCA|nnnnnnGATAATAGACTGGTCATGAGGTATTTTTAAGCAGTTGCTTAAAA INS 6 0.5% possible
CCTCCGCAGGCCTCTGCTCCCAGCA|-----------GGTCATGAGGTATTTTTAAGCAGTTGCTTAAAAAGACAG DEL -11 0.4% yes
CCTCCGCAGGCCTCTGCTCCC----|GATAATAGACTGGTCATGAGGTATTTTTAAGCAGTTGCTTAAAAAGACAG DEL -4 0.4% yes
CCTCCGCAGGCCTCTGCTCCCA---|----------TGGTCATGAGGTATTTTTAAGCAGTTGCTTAAAAAGACAG DEL -13 0.4% yes
CCTCCGCAGGCCTCTGCTCCCAGCA|nnnnnnnnnnnnnnGATAATAGACTGGTCATGAGGTATTTTTAAGCAGTT INS 14 0.3% possible
CCTCCGCAGGCCTCTGCTCCCAGCA|nnnnnnnnnnnnnGATAATAGACTGGTCATGAGGTATTTTTAAGCAGTTG INS 13 0.2% possible
CCTCCGCAGGCCTCTGCTCCCAG--|-------GACTGGTCATGAGGTATTTTTAAGCAGTTGCTTAAAAAGACAG DEL -9 0.2% yes
CCTCCGCAGGCCTCTGCTCCCAGCA|nnnnnGATAATAGACTGGTCATGAGGTATTTTTAAGCAGTTGCTTAAAAA INS 5 0.2% possible
CCTCCGCAGGCCTCTGCTCCCAGCA|nnnnnnnnnGATAATAGACTGGTCATGAGGTATTTTTAAGCAGTTGCTTA INS 9 0.2% possible
CCTCCGCAGGCCTCTGCTCCCAGCA|nnnnnnnnnnnnGATAATAGACTGGTCATGAGGTATTTTTAAGCAGTTGC INS 12 0.1% possible
CCTCCGCAGGCCTCTGCTCCCA---|------AGACTGGTCATGAGGTATTTTTAAGCAGTTGCTTAAAAAGACAG DEL -9 0.1% yes
CCTCCGCAGGCCTCTGCTCCCAGCA|--------------CATGAGGTATTTTTAAGCAGTTGCTTAAAAAGACAG DEL -14 0.1% yes
CCTCCGCAGGCCTCTGCTCCC----|----ATAGACTGGTCATGAGGTATTTTTAAGCAGTTGCTTAAAAAGACAG DEL -8 0.1% yes
TAL1 motif
GATA1 motif
Sequence InDel Type InDel Lenght (nt)
InDel 
Frequency
GATA motif 
disruption
CTAGGACTCCTGTGACTCATTACTG|TTGAGGAGATAAGAATGTGGGCTTTGGAGTCATCAAGACAGAGTTGGAAA WT 0 27.4% no
CTAGGACTCCTGTGACTCATTACTG|----------AAGAATGTGGGCTTTGGAGTCATCAAGACAGAGTTGGAAA DEL -10 6.8% yes
CTAGGACTCCTGTGACTCATTACTG|--------ATAAGAATGTGGGCTTTGGAGTCATCAAGACAGAGTTGGAAA DEL -8 4.1% yes
CTAGGACTCCTGTGACTCATTACTG|nTTGAGGAGATAAGAATGTGGGCTTTGGAGTCATCAAGACAGAGTTGGAA INS 1 3.6% no
CTAGGACTCCTGTGACTCATTAC--|-TGAGGAGATAAGAATGTGGGCTTTGGAGTCATCAAGACAGAGTTGGAAA DEL -3 3.4% no
CTAGGACTCCTGTGACTCATTACTG|------AGATAAGAATGTGGGCTTTGGAGTCATCAAGACAGAGTTGGAAA DEL -6 3.4% no
CTAGGACTCCTGTGACTCATTACTG|-TGAGGAGATAAGAATGTGGGCTTTGGAGTCATCAAGACAGAGTTGGAAA DEL -1 3.1% no
CTAGGACTCCTGTGACTCATTACTG|nnTTGAGGAGATAAGAATGTGGGCTTTGGAGTCATCAAGACAGAGTTGGA INS 2 3.0% no
CTAGGACTCCTGTGACTCATTACTG|---------TAAGAATGTGGGCTTTGGAGTCATCAAGACAGAGTTGGAAA DEL -9 2.7% yes
CTAGGACTCCTGTGACTCATTACTG|--GAGGAGATAAGAATGTGGGCTTTGGAGTCATCAAGACAGAGTTGGAAA DEL -2 2.7% no
CTAGGACTCCTGTGACTCATTACTG|-----GAGATAAGAATGTGGGCTTTGGAGTCATCAAGACAGAGTTGGAAA DEL -5 2.7% no
CTAGGACTCCTGTGACTCATTACTG|------------GAATGTGGGCTTTGGAGTCATCAAGACAGAGTTGGAAA DEL -12 2.6% yes
CTAGGACTCCTGTGACTCATTACTG|-----------AGAATGTGGGCTTTGGAGTCATCAAGACAGAGTTGGAAA DEL -11 2.5% yes
CTAGGACTCC---------------|---------------TGTGGGCTTTGGAGTCATCAAGACAGAGTTGGAAA DEL -30 2.3% yes
CTAGGACTCCTGTGACTCATTACTG|---------------TGTGGGCTTTGGAGTCATCAAGACAGAGTTGGAAA DEL -15 1.9% yes
CTAGGACTCCTGTGACTC-------|-------------AATGTGGGCTTTGGAGTCATCAAGACAGAGTTGGAAA DEL -20 1.7% yes
CTAGGACTCCTGTGACTC-------|--------------ATGTGGGCTTTGGAGTCATCAAGACAGAGTTGGAAA DEL -21 1.6% yes
CTAGGACTCCTGTGACTC-------|---------------TGTGGGCTTTGGAGTCATCAAGACAGAGTTGGAAA DEL -22 1.6% yes
CTAGGACTCCTGTGACTCATTACTG|----GGAGATAAGAATGTGGGCTTTGGAGTCATCAAGACAGAGTTGGAAA DEL -4 1.6% no
CTAGGACTCCTGTGACTCATTACTG|-------GATAAGAATGTGGGCTTTGGAGTCATCAAGACAGAGTTGGAAA DEL -7 1.4% yes
CTAGGACTCCTGTGACTCATTACTG|--------------ATGTGGGCTTTGGAGTCATCAAGACAGAGTTGGAAA DEL -14 1.3% yes
CTAGGACTCCTGTGACTCATTAC--|---------------TGTGGGCTTTGGAGTCATCAAGACAGAGTTGGAAA DEL -17 1.0% yes
CTAGGACTCC---------------|--------------ATGTGGGCTTTGGAGTCATCAAGACAGAGTTGGAAA DEL -29 1.0% yes
CTAGGACTCCTGTGACTCATTACTG|nnnTTGAGGAGATAAGAATGTGGGCTTTGGAGTCATCAAGACAGAGTTGG INS 3 1.0% no
CTAGGACTCCTGTGACTCATTACTG|nnnnnTTGAGGAGATAAGAATGTGGGCTTTGGAGTCATCAAGACAGAGTT INS 5 0.9% no
CTAGGACTCCTGTGAC---------|---------------TGTGGGCTTTGGAGTCATCAAGACAGAGTTGGAAA DEL -24 0.6% yes
CTAGGACTCCTGTGACTCATTACTG|nnnnnnnnTTGAGGAGATAAGAATGTGGGCTTTGGAGTCATCAAGACAGA INS 8 0.6% no
CTAGGACTCCTGT------------|-------------AATGTGGGCTTTGGAGTCATCAAGACAGAGTTGGAAA DEL -25 0.6% yes
CTAGGACTCC---------------|-----------AGAATGTGGGCTTTGGAGTCATCAAGACAGAGTTGGAAA DEL -26 0.5% yes
CTAGGACTCCTGTGACTCATTACTG|nnnnTTGAGGAGATAAGAATGTGGGCTTTGGAGTCATCAAGACAGAGTTG INS 4 0.4% no
CTAGGACTCCTGTGACTCATTACTG|-------------AATGTGGGCTTTGGAGTCATCAAGACAGAGTTGGAAA DEL -13 0.3% yes
CTAGGACTCCTGTGACTCATTACT-|---------------TGTGGGCTTTGGAGTCATCAAGACAGAGTTGGAAA DEL -16 0.3% yes
CTAGGACTCCTGTGACTCATTACTG|nnnnnnnnnnnnnnnTTGAGGAGATAAGAATGTGGGCTTTGGAGTCATCA INS 15 0.1% no
CTAGGACTCCTGTGACTCATTACTG|nnnnnnnTTGAGGAGATAAGAATGTGGGCTTTGGAGTCATCAAGACAGAG INS 7 0.1% no
AP1/HIF1b motif
GATA1 motif
PITX1 motif
 Supplemental figure legends 
 
Figure S1. Characterization of erythroid progenitors and precursors. Related to Figure 
1. 
(A) Representative FACS histograms showing CD34, CD36 and glycophorin A (GYPA) levels 
in HSPC, E-Prog and E-Prec.  
(B) RT-qPCR analysis of HBA, HBB, FOXO3 and STOM mRNA expression levels in HSPC, 
E-Prog and E-Prec. During erythroid commitment and differentiation, HBA and HBB 
expression levels progressively increased, while the transcription factor FOXO3 (essential for 
terminal maturation)(Liang et al., 2015) and the erythrocyte membrane protein STOM were 
expressed at high levels only in E-Prec. Transcript levels were normalized to LMNB2 mRNA. 
Data were plotted as mean with SEM. 
(C) Comparison of gene expression profiles of E-Prog, E-Prec and erythroid progenitors and 
precursors from publicly available datasets (An et al., 2014; Li et al., 2014). PCA analysis 
showed that E-Prog cluster with human erythroid progenitors (BFU-E and CFU-E), while E-
Prec exhibit gene expression profiles similar to human polychromatic erythroid precursors. 
The 2D plot show PCA coordinates for each biological replicate. Principal components (PC1 – 
PC2) are shown on the x and y axes. Abbreviations: erythroid burst-forming units, BFU-E; 
erythroid colony-forming units, CFU-E; proerythroblasts, proE; early basophilic erythroblasts, 
earlyB; late basophilic erythroblasts, lateB; polychromatic erythroblasts, polyC; 
orthochromatic erythroblasts, orthoC. 
(D) Unsupervised clustering of expression levels in HSPC, E-Prog and E-Prec of genes with 
CPM ≥ 1 in at least 3 samples (expressed genes). Blue and red indicate higher and lower 
than average expression levels, respectively. As reported by An et colleagues (An et al., 
2014), a general reduction of gene expression was observed during differentiation from E-
Prog to E-Prec.  
(E) Volcano plots showing global transcriptional changes upon erythroid commitment (left 
panel) and differentiation (right panel). Down-regulated genes are indicated in blue, up-
regulated genes in red, genes not differentially expressed in black. Differentially expressed 
genes (DEGs) were identified with absolute log2 fold change > 1 and adjusted p-value < 0.01. 
 (F) Gene Ontology enrichment analysis. Enriched Biological Process (BP) terms are shown 
on the y-axis; DEGs groups, as defined in Figure 1B, are shown on the x-axis. Dots are color-
coded based on the enrichment q-values; dot size indicates the fraction of DEGs in each BP 
term. 
 
Figure S2. Analysis of histone marks, chromatin states and regulatory elements during 
erythroid development. Related to Figure 1. 
(A) Genome coverage of histone marks in HSPC, E-Prog and E-Prec (Chi-square test).  
(B) Western blot analysis of H3K27ac levels in the nuclear fraction of HSPC, E-Prog and E-
Prec. Total H3 was used for normalization.  
(C) Definition of chromatin states using Spectacle. The heatmap shows emission probabilities 
of each histone mark for the 11-state model. 
(D) Genome coverage of chromatin states in HSPC, E-Prog and E-Prec. Active promoters 
(state 5 and 6) and enhancers (state 1 and 2) displayed reduced genome coverage in E-Prog 
and E-Prec compared to HSPC. *: p-value < 0.001 (Chi-square test). 
(E) Expression levels of genes associated to promoter regions. Promoters were classified as 
active (H3K27ac+H3K27me3-, A), weak (H3K27ac-H3K27me3-, W) or bivalent (H3K27ac-
H3K27me3+, B). For each promoter state, the boxplot shows the distribution of the expression 
levels of target genes. As control, the distribution of the expression levels of all expressed 
genes (all) was reported (Wilcoxon test). 
(F) Expression levels of genes targeted by enhancers and super-enhancers (SE). Enhancers 
were classified as active (H3K27ac+H3K27me3-, A), weak (H3K27ac-H3K27me3-, W) or 
bivalent (H3K27ac-H3K27me3+, B). For super-enhancers and each enhancer state, the 
boxplot shows the distribution of the expression levels of target genes. As control, the 
distribution of expression levels of all expressed genes (all) was reported (Wilcoxon test). 
(A, E, F) *: p-value < 0.05; **: p-value < 0.01; ***: p-value < 0.001; ****: p-value < 0.0001 
 
Figure S3. Expression levels and functional enrichment analysis of genes associated 
with stage-specific or shared promoters and enhancers. Related to Figure 1. 
 
 (A) Expression levels of genes associated with active stage-specific promoters in HSPC, E-
Prog and E-Prec. The expression levels of genes associated with stage-specific promoters 
were compared to the expression levels of the same genes in the other cell types. These 
genes showed higher expression levels in the specific stage compared to the others 
(Wilcoxon test).  
(B) Gene Ontology enrichment analysis of promoter subsets. Each row of the heatmap 
represents a promoter region. Biological Process (BP) terms enriched in each subset of 
promoters are shown.  
(C) Expression levels of genes targeted by active stage-specific enhancers in HSPC, E-Prog 
and E-Prec. The expression levels of genes associated with stage-specific enhancers were 
compared to the expression levels of the same genes in the other cell types. These genes 
showed higher expression levels in the specific stage compared to the others (Wilcoxon test).  
(D) Gene Ontology enrichment analysis of enhancer subsets. Each row of the heatmap 
represents an enhancer region. Biological Process (BP) terms enriched in each subset of 
enhancers are shown.  
(A, C) ns: not significant; *: p-value < 0.05; **: p-value < 0.01; ***: p-value < 0.001; ****: p-
value < 0.0001 
 
Figure S4. Expression levels and functional enrichment analysis of genes associated 
with stage-specific or shared super-enhancers. Related to Figure 1. 
(A) Expression levels of genes associated with HSPC (n=453 genes), E-Prog (n=401 genes), 
and E-Prec (n=110 genes) stage-specific super-enhancers (Wilcoxon test). 
(B) Gene Ontology enrichment analysis of super-enhancer subsets. Each row of the heatmap 
represents a super-enhancer. Biological Process (BP) terms enriched in each subset of 
super-enhancers are shown.  
(C, D, E) Representative stage-specific super-enhancers and expression levels of the target 
gene in HSPC (C), E-Prog (D) and E-Prec (E). DNMT3A is essential in HSPC biology. CD55 
(encoding the antigen of the Cromer blood group system) and RHD (encoding the antigen of 
the Rh blood group) are highly expressed in E-Prog and E-Prec, respectively. Data were 
plotted as mean with SEM. 
  
Figure S5. GATA1 expression along erythroid development and transcription factor 
binding site motifs in GATA-targeted genomic regions. Related to Figure 2. 
(A) GATA1 protein copy number across erythropoiesis. Data were retrieved from (Gautier et 
al., 2016). Data were plotted as mean with SEM. 
(B) Density plots of GATA2 and GATA1 ChIP-seq. 
(C) Examples of GATA2 and GATA1 peaks at known target genes. 
(D) Enrichment or depletion of transcription factor binding motifs in genomic regions targeted 
by GATA factors only in one cell population (GATA2 only in HSPC, GATA1 only in E-Prog 
and GATA1 only in E-Prec) or by GATA2 in HSPC and GATA1 in E-Prog (GATA switch) or by 
GATA1 in both E-Prog and E-Prec (GATA1 common). GATA and GATA-TAL1 binding motifs 
were enriched in all the categories.  
 
Figure S6. Regulatory regions targeted by GATA factors. Related to Figure 2. 
(A, B, C) Bar plot showing the percentage of promoters (A), enhancers (B) and super-
enhancers (C) bound by GATA factors in HSPC, E-Prog and E-Prec.  
(D) Examples of genes regulated by GATA factors (related to Figure 2E-F). CD55 and 
PDLIM1 belong to group B; STAM, NBAS, EPB41, RAPGEF2 and RNF187 belong to group 
C; MAP2K3 belongs to group F. RAPGEF2, MAP2K3 and RNF187 are down-regulated during 
murine erythropoiesis, but are upregulated during human erythropoiesis and associated with 
active regulatory elements in E-Prog and E-Prec. 
(E) Expression levels of genes reported in panel D. Data were plotted as mean with SEM. 
 
Figure S7. Enrichment analysis of transcription factor binding motifs around GATA1 
BS within regulatory regions associated with up- or down-regulated genes in E-Prog 
and E-Prec. Related to Figure 3. 
For each motif, enrichment values over genomic background are reported as log2 fold change 
for each category of GATA1 BS. GATA and GATA-TAL1 binding motifs were enriched in all 
the categories. 
 
 Figure S8. KIT expression and chromatin interactions in HUDEP-2 cells. Related to 
Figure 4. 
(A) KIT expression levels in undifferentiated (Day0) and differentiated (Day7) HUDEP-2 cells, 
as determined by RT-qPCR. Data were plotted as mean with SEM. **: p-value < 0.01 
(unpaired t-test). 
(B) Flow cytometry analysis of KIT expression in undifferentiated (Day0) and differentiated 
(Day7) HUDEP-2 cells. The percentage of KIT+ cells and the MFI (median fluorescence 
intensity) are shown. Data were plotted as mean with SEM. **: p-value < 0.01 (unpaired t-
test). 
(C) E-Prog regulatory elements and ATAC-seq signal within the KIT locus in undifferentiated 
HUDEP-2. Orange dashed boxes indicate the E-Prog-specific KIT enhancers. 
(D-E) Chromatin interactions within the KIT locus in undifferentiated (Day0) and differentiated 
(Day7) HUDEP-2 cells. We used as anchor a genomic fragment containing the enhancer I (D) 
or II (E) (flanked by solid black lines). HindIII digestion fragments of interest are flanked by 
dashed black lines. Distances on the x-axis are in kb counting from the TSS of the KIT gene. 
(C) KIT enhancer I showed a higher interaction frequency with KIT enhancer II and promoter 
in undifferentiated HUDEP-2 cells. (D) KIT enhancer II showed a higher interaction frequency 
with KIT enhancer I and promoter in undifferentiated HUDEP-2 cells.  
 
Figure S9. Disruption of GATA1 binding sites in KIT enhancers I and II. Related to 
Figure 5. 
(A) Representative analysis of GATA1 binding site disruption in enhancer I. In  BS I samples, 
a frequency ranging from 36 to 46% of GATA1 binding sites in enhancer I were modified. 
Virtually all the editing events disrupted the GATA1 binding site. Most of the editing events 
disrupted also the TAL1 motif that overlaps with the GATA1 motif (composite TAL1:GATA1 
motif). PCR products were subjected to Sanger sequencing and ICE CRISPR Analysis. InDel, 
insertion or deletion. 
(B) Representative analysis of GATA1 binding site disruption in enhancer II. To disrupt 
GATA1 binding site in enhancer II, we employed 2 gRNA flanking the binding site (5’-end and 
3’-end gRNAs). ddPCR revealed the deletion of a 67-bp fragment containing the GATA1 
 binding site in 7 to 11% of the loci. In addition, Sanger sequencing followed by ICE CRISPR 
Analysis revealed that, at the remaining loci, the 5’-end gRNA disrupted on average ~34% of 
the GATA1 binding sites. Consistently, targeted NGS sequencing of a PCR amplicon 
encompassing the GATA1 binding site in enhancer II showed that the GATA1 motif was 
disrupted in ~59% of the loci, and the AP1/HIF1b and PITX1 motifs in ~14% and ~42% of the 
loci, respectively (data not shown). InDel, insertion or deletion. 
  
 Supplemental Tables 
Table S1. Cis-regulatory regions identified in HSPC, E-Prog and E-Prec. Related to 
Figure 1. 
Regulatory 
region 
Cell 
Number of 
regions 
Average size (bp) 
Median size (bp) 
Active promoters 
HSPC 13,548 2,417.91 2,200 
E-Prog 9,788 2,594.91 2,400 
E-Prec 6,156 3,141.42 2,800 
Weak promoters 
HSPC 1,217 727.86 600 
E-Prog 4,957 1,250.31 1,000 
E-Prec 6,479 1,589.94 1,400 
Bivalent 
promoters 
HSPC 5,074 1,075.68 800 
E-Prog 5,605 1,295.24 1,200 
E-Prec 3,233 1,256.05 1,000 
Active enhancers 
HSPC 20,202 2,939.47 2,000 
E-Prog 20,083 1,857.50 1,200 
E-Prec 1,725 2,596.06 1,800 
Weak enhancers 
HSPC 27,251 1,013.06 800 
E-Prog 24,327 1,247.87 800 
E-Prec 19,051 1,478.14 1,000 
Bivalent 
enhancers 
HSPC 1,955 1,046.65 800 
E-Prog 1,991 993.47 600 
E-Prec 561 870.94 600 
Super-enhancers 
HSPC 497 32,928.37 28,800 
E-Prog 436 30,368.81 27,400 
E-Prec 135 14,594.07 12,000 
 
  
 Table S5. GATA factor binding sites identified in HSPC, E-Prog and E-Prec. Related to 
Figure 2. 
TF Cell Number of BS Average size (bp) Median size (bp) 
GATA2 
HSPC 15171 276.24 241 
E-Prog 419 456.17 453 
E-Prec 0 - - 
GATA1 
HSPC 0 - - 
E-Prog 23268 186.15 166 
E-Prec 11005 231.37 202 
 
 
Table S6. Primer for RT-qPCR analysis. Related to Figures S1 and 5. 
Primer name Sequence (5’-3’) 
HBA Forward primer CGGTCAACTTCAAGCTCCTAA 
HBA Reverse primer ACAGAAGCCAGGAACTTGTC 
HBB Forward primer GCAAGGTGAACGTGGATGAAGT 
HBB Reverse primer TAACAGCATCAGGAGTGGACAGA 
KIT Forward primer ATGGCACGGTTGAATGTAAGGC 
KIT Reverse primer TCTCCTCAACAACCTTCCACTG 
FOXO3 Forward primer TGTTGGTTTGAACGTGGGGA 
FOXO3 Reverse primer TGTCCACTTGCTGAGAGCAG 
STOM Forward primer GGAGCCAAAGGACCTGGTTT 
STOM Reverse primer GACCACACCATCCACGCTAA 
GYPA Forward primer TCCAGAAGAGGAAACCGGAGA 
GYPA Reverse primer AAAGGCACGTCTGTGTCAGG 
GATA1 Forward primer GCCCAAGAAGCGAATGATTG 
GATA1 Reverse primer GTGGTCGTTTGACAGTTAGTGCAT 
GATA2 Forward primer ACCACAAGATGAATGGACAGAA 
GATA2 Reverse primer GTCGTCTGACAATTTGCACAAC 
 
 
  
 Table S7. Primer for 3C experiments in KIT locus using promoter as anchor. Related to 
Figure 4. 
Primer name Description Sequence (5’-3’) 
-99.2 kb primer  AATTCACCTGCTCAAACCCT 
-86.4 kb primer Enhancer I AAAGACAGCATTGCGTGACC 
-76.2 kb primer  CCCCACACCCAGCCAAATTA 
-72.2 kb primer Enhancer II AGTGTACATGCTCAAGCCCA 
-44.7 kb primer  GCAGCGTGGTTTAAGAATCCC 
-27.6 kb primer  TGAACCATCAAGCCTTGCCT 
-18.8 kb primer  GGGCCTGGAAGGATGAGTTG 
-3.5 kb primer Promoter (anchor) CTGGGTGGCTGGAAGGTAAA 
 
 
Table S8. Primer for 3C experiments in KIT locus using Enhancer I as anchor. Related 
to Figure S8. 
Primer name Description Sequence (5’-3’) 
-91.0 kb primer Enhancer I (anchor) AAAGACAGCATTGCGTGACC 
-76.2 kb primer  AGACTGGACCTTCAAAATGGTG 
-72.2 kb primer Enhancer II GGGAAAGACTCCGAGTGAGC 
-70.3 kb primer  CAATTGGTCACAGCCAGTGC 
-62.2 kb primer  TTGGGGATCTGGCCATTCAG 
-42.4 kb primer  TCCACAATTGGACTGCCCTC 
-27.6 kb primer  GCTCTCTAAGGTGGCACAGT 
-14.9 kb primer  GCCATAGCATGGCATTCAAGA 
-3.5 kb primer Promoter CTGGGTGGCTGGAAGGTAAA 
 
 
  
 Table S9. Primer for 3C experiments in KIT locus using Enhancer II as anchor. Related 
to Figure S8. 
Primer name Description Sequence (5’-3’) 
-91.0 kb primer Enhancer I  AAAGACAGCATTGCGTGACC 
-76.2 kb primer  TGGAATCCTGGAAAATCGCA 
-72.2 kb primer Enhancer II 
(anchor) 
AGTGTACATGCTCAAGCCCA 
-62.2 kb primer  TTGGGGATCTGGCCATTCAG 
-42.4 kb primer  AATTGGACTGCCCTCTCCAC 
-27.6 kb primer  GCTCTCTAAGGTGGCACAGT 
-21.3 kb primer  AGACAAGACCACAAAACATAAGGA 
-14.9 kb primer  AGCCTTGTTTCTTGCCAATTCT 
-3.5 kb primer Promoter CTGGGTGGCTGGAAGGTAAA 
 
  
 Table S10. gRNAs for KIT Enhancers deletion or GATA1 BS disruption. Related to 
Figure 5. 
Name Description Sequence (5’-3’) Chr Strand Start End 
gRNA Ctr Luciferase CTTCGAAATGTCCGTTCGGT na na na na 
gRNA1 Exon 2 GCCTAATCTCGTCGCCCACG 4 - 55,561,754 55,561,776 
gRNA2 
Enhancer I  
5’-end 
GGAGATCCTAGTTTACAG 4 + 55,436,361 55,436,378 
gRNA3 
Enhancer I 
3’-end 
GTTTATGACAATCCCTCA 4 - 55,440,103 55,440,121 
gRNA4 
Enhancer I 
GATA1bs 
GACCAGTCTATTATCTGC 4 - 55,437,596 55,437,613 
gRNA5 
Enhancer II 
5’-end 
GTACACGGTATGTTGCGGGG 4 - 55,450,377 55,450,396 
gRNA6 
Enhancer II 
3’-end 
GACTGGCCACAGTCTCACGA 4 + 55,457,052 55,457,071 
gRNA7 
Enhancer II 
GATA BS 
5'-end 
CCTGTGACTCATTACTGTTG 4 + 55,451,941 55,451,960 
gRNA8 
Enhancer II 
GATA BS 
3'-end 
TTCAGCTCCACCACTAAATG 4 + 55,452,008 55,452,027 
na, not applicable 
 
  
 Table S11. Primer for detecting GATA1 binding site disruption. Related to Figure S9. 
Primer Name Description Sequence (5’-3’) 
F Enh I primer Enhancer I GATA 1 BS 
(Sanger sequencing) 
GCAAAGCCTTTCGTTTTGCC 
R Enh I primer TCCCTGACGCTAGAAGGAGT 
F Enh II primer Enhancer II GATA 1 BS 
(Sanger sequencing) 
CGAATTTATGCGTGGGTGCC 
R Enh II primer AATCAGCTCCTGGGCTTTGG 
F Enh II ddPCR primer Enhancer II GATA 1 BS 
(ddPCR) 
CCAAGAAACATCACTAGGACTCC 
R Enh II ddPCR primer CGAGGCTTAGAGAGGTGCAG 
F KIT prom primer KIT promoter, Chr4 
(ddPCR) 
GCAGTTAAGAGCCCTAGCCC 
R KIT prom primer GCTGCCAACCCCAGTAATGA 
F Enh II NGS primer Enhancer II GATA 1 BS 
(NGS) 
ACAACTTTCTACTCTCTCATGCTG 
R Enh II NGS primer AGAATCCAGGTTGCTGCAGA 
 
  
 Transparent methods 
Culture and purification of primary cells 
Isolation of hematopoietic stem/progenitor cells (HSPC) 
Human CD34+ cells were purified from umbilical cord blood (CB) samples obtained from 
healthy donors. CB samples eligible for research purposes were obtained thanks to a 
convention with the cord blood bank of Saint Louis Hospital (Paris, France). Experiments 
were performed in accordance with the Declaration of Helsinki. This study was approved by 
the regional investigational review board (DC 2014-2272, CPP Ile-de-France II “Hôpital 
Necker-Enfants malades”). Informed consent was obtained from all subjects. Mononuclear 
cells derived from different healthy donors were pooled and isolated by gradient separation 
(Lymphocytes separation medium, Eurobio), washed twice with phosphate-buffered saline 
(PBS) completed with 2% fetal bovine serum (FBS, Hyclone), and then CD34+ cells were 
purified by immunomagnetic sorting (Indirect CD34 MicroBead Kit, human Miltenyi Biotec). 
The purity of CD34+ sorted cell populations was evaluated by flow cytometry. 
Culture of HSPC 
CD34+ cells were seeded at 0.5 x 106 cells/ml and cultured for 36 hours in an IMDM-based 
expansion medium (Lonza) containing 20% FBS (Hyclone) and supplemented with 100 ng/ml 
human stem cell factor (hSCF), 100 ng/ml human Flt3-ligand (hFlt3-l), 20 ng/ml human 
trombopoietin (hTPO) and 20 ng/ml human interleukin-6 (hIL-6) (PeproTech). Cells were 
harvested after 36 hours. 
Culture and isolation of erythroid progenitors (E-Prog) and erythroid precursors (E-Prec) 
CD34+ cells were cultured as described by Roselli and colleagues (Roselli et al., 2010). Cells 
were seeded at 105 cells/ml in StemSpan medium (Stem Cell Technologies) containing 20% 
FBS (Hyclone) and supplemented with 50 ng/ml hSCF (Peprotech), 1 U/ml human 
erythropoietin (EPO; Janssen), 1 ng/ml hIL-3 (Peprotech), 10-6 M dexamethasone (Sigma-
Aldrich), and 10-6 M ß-estradiol (Sigma-Aldrich). At day 7, cells were grown in StemSpan 
medium with 10% FBS supplemented with 2 U/ml human EPO, and at day 10 they were 
cultured in StemSpan containing only 10% FBS. 
 To isolate CD36+ erythroid progenitors (E-Prog) at day 5, cells were labeled with FITC-
conjugated anti-CD36 antibody and selected using magnetic-activated cell sorting (MACS) 
technology in combination with anti-FITC microbeads (Miltenyi Biotec), following 
manufacturer’s instructions. Erythroid precursors (E-Prec) were collected at day 11. 
 
Flow cytometry analysis 
Cells were labeled with antibodies against CD34 (CD34-FITC [345801], BD Biosciences; 
CD34-PE [345802], BD Biosciences), CD36 (CD36-FITC [555454], BD Pharmingen), 
CD235a/GYPA (CD235a-APC [551336], BD Pharmingen) and CD117/KIT (CD117-PE 
[332785], BD Biosciences) surface markers, following manufacturer’s instructions. FACS 
analysis was performed using LSRFortessa X-20 flow cytometer (BD Biosciences).  
 
RT-qPCR  
RNA was reverse-transcribed using SuperScript First-Strand Synthesis System for RT-PCR 
(Invitrogen). RT-qPCR was performed using iTaq Universal SYBR Green Supermix (Bio-
Rad). LMNB2 primers were used as an internal control. RT-qPCR data were analyzed using 
the 2-ΔΔCt method. Primer sequences are listed in Table S6. 
 
Western Blot 
To extract nuclear proteins, 3x106 cells were resuspended in 100 µl lysis buffer (20 mM 
HEPES pH 7.8, 5 mM potassium acetate, 0.5 mM MgCl2 in water), then crushed 25 times in a 
douncer. Lysate was centrifuged for 5 min at 1,500 x g. Nuclei containing pellets were 
resuspended in 100 µl sonication buffer (50 mM Tris-HCl pH 8, 1 mM EDTA pH 8, 0.5 mM 
EGTA, 1% Triton X-100, 0.1% SDS, 0.1% Na-deoxycholate, 140 mM NaCl in water) and 
sonicated using Bioruptor Pico (Diagenode) for 10 cycles of a 30 s ON/30 s OFF program. 
Protein concentration was measured using BCA protein assay kit (Pierce).  
Western Blot analysis was performed using Mini Gel Tank (Thermo) by loading the equivalent 
of 3x105 cells lysate per well. SDS PAGE was performed using NuPage Bis-Tris 4-12% gel 
(Thermo) in 1X MOPS buffer (Thermo) for 2 hours at 100 V. Protein transfer was performed 
 on PVDF membrane (Millipore) pre-activated in ethanol, using a Mini Blot Transfer Module 
(Thermo). After transfer, membranes were incubated for 1 hour in TBS-Tween buffer (50 mM 
Tris-HCl pH8, 150 mM NaCl, 0,1% Tween 20 in water) completed with 5% skim milk.  
Primary antibody staining was performed by incubating the membranes in TBS-Tween buffer 
with 5% skim milk at 4°C overnight on a shaker using rabbit anti-GATA1 antibody (Abcam, 
ab11852, diluted 1:400), rabbit anti-GATA2 antibody (Santa Cruz sc299, diluted 1:200), rabbit 
anti-H3K27ac antibody (Abcam, ab4729, diluted 1 µg/ml) and rabbit anti-H3 antibody (Abcam, 
ab1791, diluted 1:1000). Blots were washed several times in TBS-Tween and incubated 1 
hour at room temperature (RT) in TBS-Tween buffer with 5% skim milk containing anti-rabbit 
HRP antibody (Thermo, A27036, diluted 1:3000). After 3 washes in TBS-Tween, membranes 
were incubated for 1 minute with ECL substrate (Pierce) and exposed to film (Hyperfilm ECL, 
Amersham). The film was developed following manufacturer’s instructions. 
 
RNA-seq 
RNA extraction, library preparation and sequencing 
Total RNA was extracted from 1-2x106 HSPC, E-Prog and E-Prec (3 biological replicates for 
each stage) using RNeasy Micro kit (QIAGEN). RNA quality was assessed using the Agilent 
High Sensitivity RNA ScreenTape System (Agilent Technologies): RNA Integrity Number 
(RIN) was > 8 for all the samples. Libraries were prepared starting with 1 µg of total RNA 
using TruSeq Stranded mRNA kit (Illumina) and 100 bp paired-end sequences were 
generated on the HiSeq 2500 instrument (Illumina). About 30 million reads per sample were 
obtained. 
Bioinformatic analysis 
Reads quality was checked using FastQC 
(http://www.bioinformatics.babraham.ac.uk/projects/fastqc/). Raw reads were mapped to the 
human reference genome (hg19 build) using STAR (Dobin et al., 2013). Raw gene counts 
were obtained using HTSeq (Anders et al., 2015), with stranded option and Ensembl gene 
annotation (GRCh37 Release 82), and then normalized according to library size to obtain 
counts per million (CPM) values. Only genes with a CPM ≥ 1 in at least 3 samples were 
 retained for subsequent analyses. DESeq2 R package was employed to estimate size factors 
and dispersion in all samples and then define differentially expressed genes (DEGs) between 
samples of consecutive stages (Love et al., 2014). Functional enrichment analysis of gene 
ontology (GO) biological process (BP) categories was performed using clusterProfiler R 
package (Yu et al., 2012). We used Principal Component Analysis (PCA) to compare E-Prog 
and E-Prec gene expression profiles with public transcriptomic datasets obtained from human 
erythroid progenitors (BFU-E and CFU-E) and erythroid precursors (proerythroblasts, proE; 
early basophilic erythroblasts, earlyB; late basophilic erythroblasts, lateB; polychromatic 
erythroblasts, polyC; orthochromatic erythroblasts, orthoC) (An et al., 2014; Li et al., 2014). 
 
ChIP-seq 
ChIP assay 
Chromatin from E-Prog and E-Prec (derived from pools of HSPC obtained from multiple 
donors) was prepared after cross-linking for 10 minutes at RT with 1% formaldehyde-
containing medium. Nuclear extracts were sonicated using the Bioruptor Pico Sonication 
System (Diagenode) to obtain DNA fragments around 150-200 bp in length. For histone 
modifications, chromatin obtained from 107 cells was immunoprecipitated overnight with 10 µg 
of antibodies against H3K4me1 (ab8895, Abcam), H3K4me3 (ab8580, Abcam), H3K27ac 
(ab4729, Abcam), and H3K27me3 (07-449, Millipore). For transcription factors, chromatin 
obtained from 3x107 cells was immunoprecipitated overnight with 30 µg of antibodies against 
GATA1 (ab11852, Abcam) and GATA2 (sc-9008, Santa Cruz Biotechnology). ChIP assay 
was performed as previously described (Cui et al., 2009; Romano et al., 2016). 
Library preparation and sequencing 
ChIP-seq libraries for E-Prog and E-Prec were prepared from 1 ng of immunoprecipitated (IP) 
DNA and 5 ng of control DNA (Input: non-immunoprecipitated chromatin fragments) following 
the Diagenode Microplex Library preparation kit. Libraries quality was checked by capillary 
electrophoresis (Tape Station, Agilent) with the High sensitivity D1000 assay and quantified 
by Real Time q-PCR using the kit from KAPA Biosystems (Roche). Each library was 
sequenced in one MiSeq Illumina RUN and 50 bp single-end reads were generated. At least 
20 million reads per sample were obtained. 
 Bioinformatics data analysis 
Read quality was checked using FastQC 
(http://www.bioinformatics.babraham.ac.uk/projects/fastqc/). Raw reads were mapped against 
the human reference genome (hg19 build) using Bowtie allowing up to 2 mismatches 
(Langmead et al., 2009). Then, each BAM file was processed using SAMtools and converted 
into a bed file using BEDTools (Li et al., 2009; Quinlan and Hall, 2010). Sample quality was 
evaluated using the cross-correlation analysis implemented in spp R package (Kharchenko et 
al., 2008). Density plots of GATA2 and GATA1 ChIP-seq (Figure S5B) were generated using 
ngs.plot (Shen et al., 2014) and a 4-kb window centered on gene transcription start site 
(TSS). ChIP-seq peak calling was performed using MACS2, with a q-value threshold of 0.05, 
and --broad option for histone modifications (Zhang et al., 2008). Input data were used to 
model the background noise. HSPC raw ChIP-seq data were downloaded from the Gene 
Expression Omnibus (GEO) GSE70660 and GSE45144 (H3K4me3: GSM1816072, 
H3K4me1: GSM1816068, H3K27ac: GSM1816075, H3K27me3: GSM1816079, GATA1: 
GSM1816081, GATA2: GSM1097883, input: GSM1816095) and analyzed as described 
above for E-Prog and E-Prec. The antibodies used in HSPC were the same used in E-Prog 
and E-Prec except for H3K4me3 antibody (04-745; Millipore). 
Motif finding analysis on GATA factor BS was performed using the findMotifsGenome function 
of Homer software (Heinz et al., 2010). Motifs were searched in 200-bp windows centered on 
peak summits.  
 
Definition of chromatin states and regulatory regions  
Chromatin states were defined using Spectacle (Song and Chen, 2015), training the hidden 
Markov model (HMM) with regions enriched in histone modifications in the 3 cell stages, 
setting the number of internal states to 11, and using bins of 200 bp. States with high 
emission probabilities for H3K4me3 were defined as promoter-like, while states with high 
emission probabilities for H3K4me1 and low for H3K4me3 were defined as enhancer-like. 
Overall, we defined 5 promoter states, 4 enhancer states, a polycomb-repressed state, and a 
quiescent state devoid of any histone mark (Figure S2C). Specifically, based on the emission 
probabilities of H3K27ac and H3K27me3, promoter and enhancer chromatin states were 
 labeled as active (H3K27ac+H3K27me3-), weak (H3K27ac-H3K27me3-) or bivalent (H3K27ac-
H3K27me3+).  
Genomic segments with an “active promoter” state were merged with contiguous genomic 
segments with “active promoter” and “weak promoter” states (if present) to define active 
promoters; genomic segments with a “bivalent promoter” state were merged with contiguous 
genomic segments with a “weak promoter” state (if present) to define bivalent promoters; the 
remaining genomic segments with a “weak promoter” state were defined weak promoters. 
The same strategy was applied to define active, weak and bivalent enhancers. Finally, we 
retained only promoters at a distance lower than 5 kb from Ensembl gene TSSs and 
enhancers at a distance higher than 5 kb from Ensembl gene TSSs. 
Active enhancers were used as constituent enhancers for super-enhancer identification. 
Enhancers were stitched together and super-enhancers were defined using the ROSE 
algorithm (Lovén et al., 2013; Whyte et al., 2013), with stitching distance of 10 kb and 
promoter exclusion zone of 10 kb around Ensembl gene TSSs. H3K27ac signal was used for 
enhancer ranking. The number of regulatory regions defined at each stage of erythroid 
development, and their average and median size, are reported in Table S1. 
Regulatory regions were annotated to the nearest 3 genes (with a maximum distance of 100 
kb). Functional enrichment analysis of gene ontology (GO) biological process (BP) categories 
was performed using clusterProfiler R package (Yu et al., 2012).  
 
Identification of epigenetic dynamics in erythropoiesis 
To study the dynamic changes in the usage of regulatory elements (promoters, enhancers 
and super-enhancers) during erythroid development, we generated a unique reference list 
containing active, weak and bivalent regulatory elements by merging the genomic regions 
identified at each stage, using the merge and multiintersect functions of the BEDTools suite 
(Quinlan and Hall, 2010) (Figure 1F-H).  
We then integrated the analysis of the dynamics of regulatory regions with the differential 
expression analysis (Figure 3A). Briefly, for each DEG, we quantified the total extension (in 
kb) of each type of regulatory elements (active, weak, and bivalent promoters and enhancers) 
by summing up the size of all gene-associated regulatory regions in each cell type. We 
 obtained a gene-centered matrix containing the coverage of the 6 types of regulatory 
elements associated to each DEG for each cell stage. Finally, we used the k-means 
clustering algorithm to identify clusters of DEGs sharing similar epigenetic landscapes (i.e., 
coverage of regulatory regions). In k-means, the silhouette method was used to determine the 
optimal number of 19 clusters (as local maximum). The statistical significance of the 
association of each cluster with gene expression patterns and transcription factor binding 
sites was assessed using Fisher’s exact test. 
 
ATAC-seq 
Raw data of ATAC-seq performed in undifferentiated HUDEP-2 cells were downloaded from 
the Gene Expression Omnibus (GEO) public database (GSE74977) (Masuda et al., 2016). 
Raw reads were trimmed to remove adapter sequences and mapped against the human 
reference genome (hg19 build) using Bowtie2 (Langmead and Salzberg, 2012). Then, the 
BAM file was processed using SAMtools to remove unmapped, not primary alignments, 
supplementary alignments, reads with alignment quality below 30 and to keep only properly 
paired reads (Li et al., 2009). Duplicates were also removed together with reads mapping on 
mitochondrial chromosome. The resulting BAM file was used to generate a normalized 
coverage track file (bigwig). 
 
HUDEP-2 cell culture 
HUDEP-2 cells were cultured as described in Antoniani et al. (2018) (Antoniani et al., 2018). 
Briefly, HUDEP-2 cells were expanded in StemSpan medium (Stem Cell Technologies) 
supplemented with 1 µg/ml doxycycline (Sigma-Aldrich), 100 ng/ml hSCF (Peprotech), 3 U/ml 
EPO (Janssen) and 10-6 M dexamethasone (Sigma-Aldrich). HUDEP-2 cells were 
differentiated for 7 days in IMDM medium (Lonza) containing 5% AB human serum (Biowest) 
and supplemented with 1 µg/ml doxycycline (Sigma-Aldrich), 100 ng/ml hSCF (Peprotech), 3 
U/ml EPO (Janssen), 10 µg/ml human insulin (Sigma-Aldrich), 330 µg/ml holo-transferrin 
(R&D SYSTEMS) and 2 U/ml heparin (Sigma-Aldrich). Flow cytometry analysis of erythroid 
markers were performed to monitor differentiation of HUDEP-2 cells (Antoniani et al., 2018). 
 
 Chromosome Conformation Capture  
Chromosome conformation capture (3C) assays were performed as described in Hagège et 
al. (2007) (Hagège et al., 2007). Briefly, HUDEP-2 cells were cross-linked for 10 minutes at 
RT with 1% formaldehyde-containing medium. Crosslinking was quenched by addition of a 3X 
glycine solution to reach a final concentration of 0.125 M. Nuclei obtained from 2x107 cells 
were digested with HindIII restriction enzyme overnight at 37 °C while shaking at 900 rpm. 
The digestion reaction was stopped by addition of SDS (2% final concentration) and heat 
inactivation at 65 °C for 30 minutes while shaking at 900 rpm. DNA fragments were diluted 
and ligated using the Quick Ligase (NEB) for 4 hours at 16 °C, followed by an additional step 
of 30 minutes at RT, while shaking at 900 rpm. After Protease K and RNase A treatment, and 
reverse cross-linking, ligation products were purified by phenol-chloroform extraction and 
ethanol precipitation. Ligation products were amplified by qPCR using SYBR Green PCR 
Master Mix (Applied Biosystems). A control template of randomly ligated DNA fragments was 
prepared by digestion and ligation of a bacterial artificial chromosome (BAC) containing the 
human KIT locus (RP11-959G16). This control template was used to generate a standard 
curve and quantify the interaction frequencies. To reduce variability between samples, 
interaction frequencies detected in the KIT locus were normalized to the interaction frequency 
between two restriction fragments in the ERCC3 locus, whose spatial conformation was 
assumed similar in all analyzed samples (Palstra et al., 2003). Primer sequences used to 
evaluate the interaction frequencies are listed in Tables S7-9. 
 
CRISPR/Cas9 genome editing experiments 
Single guide RNAs (gRNAs) were designed using ZIFIT and CRISPOR tools (Haeussler et 
al., 2016; Sander et al., 2010, 2007). COSMID tool was used to select sequence-specific and 
efficient 18-20 bp-long gRNAs (Cradick et al., 2014). Plasmids expressing Cas9-GFP 
(pMJ920) and gRNAs (MLM3636) were purchased from Addgene (plasmid # 42234 and 
43860). gRNA spacers were cloned in the MLM3636 plasmid or in the MA128 plasmid 
(provided by Dr. Mario Amendola, Genethon, France) containing an optimized gRNA scaffold 
(Dang et al., 2015). Sequences and genomic coordinates (hg19 build) of gRNAs are listed in 
Table S10. HUDEP-2 cells (1x106) were transfected with 4 µg of a Cas9-GFP expressing 
plasmid and 0.8-1.6 ug of each gRNA-containing vector using Nucleofector I (L-29 program; 
 Lonza) and AMAXA Cell Line Nucleofector Kit V (VCA-1003). FACS analyses were performed 
24 hours after transfection using LSRFortessa X-20 flow cytometer (BD Biosciences) to 
evaluate GFP and KIT (CD117-PE [332785], BD Biosciences) expression levels. GFP+ cells 
were sorted using SH800 Cell Sorter (Sony Biotechnology) for DNA and RNA extraction.  To 
evaluate editing efficiency at gRNA target sites, we performed PCR followed by Sanger 
sequencing and ICE CRISPR Analysis Tool (Synthego) (Hsiau et al., 2018). Digital Droplet PCR 
(ddPCR) was performed using EvaGreen mix (Biorad) to quantify the frequency of a 60-bp 
deletion encompassing the GATA1 binding site in enhancer II. Control primers annealing to a 
neighboring genomic region (KIT promoter) were used as DNA loading control. Primers use 
for PCR amplification and Sanger sequencing and for ddPCR are listed in Table S11. 
 
Statistical analyses 
Chi-square tests were used to compare the genome coverage of histone modifications and 
chromatin states (Figure S2). Wilcoxon tests were used to compare expression levels 
distributions (Figure S2, S3 and S4). Unpaired t tests were used to compare expression 
levels measured by RT-qPCR and FACS analysis (Figure 4, 5 and Figure S8). Wilcoxon 
tests were performed in R (v3.3.1); Chi-square and unpaired t tests were performed in Prism6 
software (GraphPad, La Jolla, CA, USA). The threshold for statistical significance was set to 
p-value < 0.05. 
 
Data and software availability 
All RNA-seq and ChIP-seq data have been deposited in Gene Expression Omnibus under 
accession number GSE124165.  
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